



# Oral formulations in SyrSpend® SF for prescribers and pharmacists

## Active Pharmaceutical Ingredients

Version 1.0 | 01/21

Active Pharmaceutical Ingredient (API)	Concentration	Common indication	Physical and chemical stability*
Acetaminophen	50 mg/ml	Pain	90 days
Acetazolamide	25 mg/ml	Epilepsy	90 days
		Glaucoma	
Allopurinol	20 mg/ml	Hyperuricaemia	90 days
Alprazolam	1 mg/ml	Anxiety & panic disorders	90 days
Amiodarone HCl	5 mg/ml	Cardiac arrhythmias	90 days
Amitriptyline HCl	10 mg/ml	Depression	90 days
		Neuropathy	
		Pain	
Amlodipine (as besylate)	1 mg/ml	Angina pectoris	90 days
		Hypertension	
Atenolol	1 - 5 mg/ml	Angina pectoris	60 - 90 days
		Cardiac arrhythmias	
		Hypertension	
		Migraine	
		Myocardial infarction	
Atropine sulfate	0.1 mg/ml	Bradycardia	90 days
Azathioprine	50 mg/ml	Hepatitis	14 days
		Transplantation	
Baclofen	2 - 10 mg/ml	Spasms	90 days
Caffeine	10 mg/ml	Neonatal apnoea	90 days
		Pain	
Captopril	0.8 mg/ml	Diabetic nephropathy	14 days
		Heart failure	14 days
		Hypertension	14 days
		Myocardial infarction	14 days
Carbamazepine	25 mg/ml	Epilepsy	90 days
Carvedilol	1 - 5 mg/ml	Angina pectoris	90 days
		Heart failure	
		Hypertension	
		Myocardial infarction	
Celecoxib	10 mg/ml	Juvenile idiopathic arthritis	90 days
		Osteoarthritis	
		Pain	
		Rheumatoid arthritis	
Chloral hydrate	100 mg/ml	Insomnia	60 days
		Sedation	
Chloroquine phosphate	15 mg/ml	Malaria	90 days
Cholecalciferol (vit. D3)	50000 IU/ml	Vitamin deficiencies	90 days
Ciprofloxacin HCl	50 mg/ml	Infections	60 - 90 days
	5 mg/ml	Anxiety & panic disorders	90 days
		Depression	
		Nocturnal enuresis	

\*For detailed information, please be referred to the Fagron SyrSpend SF compatibility table or Compounding Matters



Active Pharmaceutical Ingredient (API)	Concentration	Common indication	Physical and chemical stability*
Clonazepam	0.2 mg/ml	Anxiety & panic disorders	90 days
		Epilepsy	
Clonidine HCl	0.1 mg/ml	Anxiety & panic disorders	7 days
		Diarrhoea	
		Hypertension	
		Pain	
Clopidogrel (as bisulfate)	5 mg/ml	Myocardial infarction	30 days
		Thromboembolism	
Cloxacillin	50 mg/ml	Infections	5 days
Clozapine	25 mg/ml	Anxiety & panic disorders	60 - 90 days
		Psychoses	
		Sedation	
Cyclosporine	100 mg/ml	Eczema	90 days
		Psoriasis	
		Rheumatoid arthritis	
		Transplantation	
Dapsone	2 mg/ml	Leprosy	90 days
Darunavir / Cobicistat	20 / 3.75 mg/ml	Infections	7 days
Dexamethasone	1 mg/ml	Oral corticosteroid	90 days
Diclofenac sodium	5 mg/ml	Pain	90 days
		Rheumatoid arthritis	
Diltiazem HCl	12 mg/ml	Angina pectoris	90 days
		Cardiac arrhythmias	
		Hypertension	
Dipyridamole	10 mg/ml	Thromboembolism	90 days
Domperidone	5 mg/ml	Nausea & vomiting	90 days
Doxycycline	2 - 10 mg/ml	Infections	90 days
Enalapril maleate	1 mg/ml	Heart failure	90 days
		Hypertension	
Esomeprazole magnesium	3 mg/ml	Dyspepsia	60 days
		Oesophageal reflux	
		Peptic ulcers	
Ethambutol 2 HCl	50 - 100 mg/ml	Infections	90 days
Flecainide acetate	20 mg/ml	Cardiac arrhythmias	90 days
Fluoxetine HCl	2 mg/ml	Anxiety & panic disorders	90 days
		Depression	
Folic acid	1 mg/ml	Vitamin deficiencies	90 days
Furosemide	10 mg/ml	Hypertension	14 days
		Oedema	
Gabapentin	50 mg/ml	Epilepsy	90 days
		Neuropathy	
		Pain	
Glutamine	250 mg/ml	Oral mucositis	90 days

\*For detailed information, please be referred to the Fagron SyrSpend SF compatibility table or Compounding Matters



Active Pharmaceutical Ingredient (API)	Concentration	Common indication	Physical and chemical stability*
Glycopyrrolate (glycopyrronium bromide)	0.5 mg/ml	Asthma & COPD	90 days
		Peptic ulcers	
Griseofulvin	25 mg/ml	Infections	90 days
Haloperidol	0.5 mg/ml	Anxiety & panic disorders	90 days
		Nausea & vomiting	
		Psychoses	
Hydralazine HCl	4 mg/ml	Hypertension	30 days
Hydrochlorothiazide	2 - 5 mg/ml	Heart failure	90 days
		Hyperaldosteronism	
		Hypertension	
		Oedema	
Hydrocortisone	1 mg/ml	Oral corticosteroid	90 days
Hydrocortisone hemisuccinate	2 mg/ml	Oral corticosteroid	60 days
Hydrocortisone sodium phosphate	2 mg/ml	Oral corticosteroid	60 days
Hydroxychloroquine sulfate	25 - 50 mg/ml	Infections	90 days
		Malaria	
Imipramine HCl	5 mg/ml	Depression	90 days
		Pain	
Isoniazid	10 mg/ml	Tuberculosis	90 days
Itraconazole	20 mg/ml	Candidiasis	90 days
		Systemic fungal infections	
Ketoconazole	20 mg/ml	Systemic fungal infections	90 days
Ketoprofen	20 mg/ml	Pain	90 days
		Rheumatoid arthritis	
Labetalol HCl	40 mg/ml	Hypertension	90 days
Lamotrigine	1 mg/ml	Epilepsy	90 days
Levodopa / Carbidopa	5 - 10 / 1.25 - 2.5 mg/ml	Parkinson's disease	60 days
Levofloxacin	50 mg/ml	Infections	90 days
		Tuberculosis	
Levothyroxine Sodium (T4)	25 microgram/ml	Hypothyroidism	90 days
Lisinopril (as dihydrate)	1 mg/ml	Diabetic nephropathy	90 days
		Heart failure	
		Hypertension	
		Myocardial infarction	
Lomustine	4 - 10 mg/ml	Malignancies	90 days
Loperamide HCl	1 mg/ml	Diarrhoea	90 days
Lorazepam	1 mg/ml	Anxiety & panic disorders	60 - 90 days
		Epilepsy	
		Insomnia	
Mebeverine HCl	10 mg/ml	Inflammatory bowel disease	90 days
Melatonin	3 mg/ml	Insomnia	90 days
		Jet lag	
Mercaptopurine	10 mg/ml	Leukaemia	90 days

\*For detailed information, please be referred to the Fagron SyrSpend SF compatibility table or Compounding Matters



Active Pharmaceutical Ingredient (API)	Concentration	Common indication	Physical and chemical stability*
Methadone HCl	10 mg/ml	Pain	90 days
Methotrexate	2.5 mg/ml	Malignancies	90 days
		Psoriasis	
		Rheumatoid arthritis	
Methyldopa	50 mg/ml	Hypertension	60 days
Metoprolol tartrate	10 mg/ml	Angina pectoris	90 days
		Cardiac arrhythmias	
		Heart failure	
		Hypertension	
		Migraine	
		Myocardial infarction	
Metronidazole benzoate	80 mg/ml	Infections	90 days
		Peptic ulcers	
		Rosacea	
Midazolam (as HCl)	1 mg/ml	Epilepsy	60 days
		Insomnia	
Minocycline HCl	10 mg/ml	Infections	60 days
		Leprosy	
Nadolol	10 mg/ml	Angina pectoris	90 days
		Cardiac arrhythmias	
		Hypertension	
		Hyperthyroidism	
		Migraine	
Naltrexone HCl	1 mg/ml	Alcohol dependence	90 days
		Opioid dependence	
Naproxen	25 mg/ml	Gout	90 days
		Migraine	
		Pain	
		Rheumatoid arthritis	
Nifedipine	4 mg/ml	Angina pectoris	90 days
		Hypertension	
Nitrendipine	5 mg/ml	Hypertension	60 days
Nitrofurantoin	2 mg/ml	Urinary - tract infections	90 days
Omeprazole	2 - 5 mg/ml	Dyspepsia	90 days
		Oesophageal reflux	
		Peptic ulcers	
Ondansetron HCl	0.8 mg/ml	Nausea & vomiting	90 days
Oseltamivir (as phosphate)	6 - 15 mg/ml	Infections	90 days
Oxandrolone	3 mg/ml	Promote weight gain	90 days
Pantoprazole sodium	3 mg/ml	Dyspepsia	60 days
		Oesophageal reflux	
		Peptic ulcers	
Paracetamol	50 mg/ml	Pain	90 days

\*For detailed information, please be referred to the Fagron SyrSpend SF compatibility table or Compounding Matters

Active Pharmaceutical Ingredient (API)	Concentration	Common indication	Physical and chemical stability*
Penicillamine	50 mg/ml	Cystinuria	90 days
		Hepatitis	
		Lead poisoning	
		Rheumatoid arthritis	
		Wilson's disease	
Pentoxifylline	20 mg/ml	Vascular disorders	90 days
Phenobarbital	9 - 15 mg/ml	Epilepsy	90 days
Phenytoin	15 mg/ml	Epilepsy	90 days
		Neuropathy	
Prednisolone sodium phosphate	1.5 mg/ml	Oral corticosteroid	30 days
Prednisone	5 mg/ml	Oral corticosteroid	60 days
Pregabalin	20 mg/ml	Anxiety & panic disorders	90 days
		Epilepsy	
		Pain	
Procarbazine HCl	10 mg/ml	Malignancies	30 days
Propranolol HCl	0.5 - 5 mg/ml	Angina pectoris	90 days
		Cardiac arrhythmias	
		Hypertension	
		Migraine	
		Myocardial infarction	
Propylthiouracil	5 mg/ml	Hyperthyroidism	90 days
Pyrazinamide	100 mg/ml	Tuberculosis	90 days
Pyridoxine HCl (vit.B6)	50 mg/ml	Vitamin deficiencies	90 days
Quinidine sulfate	10 mg/ml	Cardiac arrhythmias	90 days
Ranitidine HCl	14 mg/ml	Dyspepsia	36 - 58 days
		Oesophageal reflux	
		Zollinger - Ellison syndrome	
Riboflavin (vit.B2)	10 mg/ml	Vitamin deficiencies	90 days
Rifampin (rifampicin)	25 mg/ml	Infections	60 days
Sertraline HCl	10 mg/ml	Anxiety & panic disorders	90 days
		Depression	
Sildenafil citrate	2.5 mg/ml	Pulmonary arterial hypertension	92 days
Simvastatin	1 mg/ml	Hyperlipidaemia	90 days
Sotalol HCl	5 mg/ml	Cardiac arrhythmias	90 days
Spironolactone	2 - 25 mg/ml	Heart failure	90 days
		Hyperaldosteronism	
		Oedema	
Spironolactone / hydrochlorothiazide	5 / 5 mg/ml	Hyperaldosteronism	90 days
		Hypertension	
		Oedema	
		Heart failure	
Sulfadiazine	100 mg/ml	Infections	90 days
		Toxoplasmosis	

\*For detailed information, please be referred to the Fagron SyrSpend SF compatibility table or Compounding Matters



Active Pharmaceutical Ingredient (API)	Concentration	Common indication	Physical and chemical stability*
Sulfasalazine	100 mg/ml	Inflammatory bowel disease	90 days
		Rheumatoid arthritis	
Tacrolimus (as monohydrate)	0.5 - 1 mg/ml	Organ and tissue transplantation	90 days
		Rheumatoid arthritis	
Terbinafine HCl	25 mg/ml	Candidiasis	90 days
		Systemic fungal infections	
Tetracycline HCl	25 mg/ml	Acne	90 days
		Infections	
		Rosacea	
Thiamine HCl (vit. B1)	100 mg/ml	Vitamin deficiencies	90 days
Thioguanine	2.5 mg/ml	Leukaemia	90 days
Tiagabine HCl	1 mg/ml	Epilepsy	30 - 90 days
Topiramate	5 mg/ml	Epilepsy	90 days
		Migraine	
		Neuropathy	
Tramadol HCl	5 - 30 mg/ml	Pain	90 days
Trimethoprim	10 mg/ml	Infections	90 days
Ursodiol (ursodeoxycholic acid)	20 - 30 mg/ml	Biliary cirrhosis	66 - 90 days
		Gallstones	
Valsartan	4 mg/ml	Heart failure	90 days
		Hypertension	
		Myocardial infarction	
Vancomycin HCl	25 - 50 mg/ml	Infections	90 days
Verapamil HCl	50 mg/ml	Angina pectoris	60 days
		Cardiac arrhythmias	
		Hypertension	
		Myocardial infarction	
Warfarin sodium	1 mg/ml	Myocardial infarction	10 - 44 days
		Thromboembolism	
Zonisamide	10 mg/ml	Epilepsy	90 days
		Parkinson's disease	

\*For detailed information, please be referred to the Fagron SyrSpend SF compatibility table or Compounding Matters

## Disclaimer

While a great deal of effort has been made to ensure the accuracy of the information contained herein, no claims are made as to the uses, safety, efficacy, or bioavailability of these recommendations. The information cannot be construed as (medical) advice, recommendation, or opinion. Health professionals using this information are advised to do so solely if appropriate in their own professional opinion and judgment. Fagron does not accept and cannot be held responsible or liable in any case for the information contained here.

